Arterial hypertension can lead to severe consequences, including fatal cardiovascular events. In order to treat patients with arterial hypertension, a group of calcium channel blockers is used, in particular, the representative of the third generation of derivatives of dihydropyridine - lercanidipine. In recent years, a number of clinical studies have been conducted that have been published on international medical resources and in journals. According to the results of meta-analyzes and studies, the efficacy of lercanidipine in the steady reduction of systolic and diastolic blood pressure was noted, as well as a number of its additional possibilities were noted: nephro- and cardioprotective effects, antioxidant, anti-inflammatory and anti-atherogenic effects. According to studies, the drug is well tolerated by patients with comorbid pathology, and can also be used safely in elderly patients